Take a look at some of Monday's midday movers:
AT&T (NYSE:T) and DirecTV (DTV) moved lower following the announcement AT&T would buy the satellite TV provider for $48.5 billion in cash and stock. AT&T could walk away from the merger if DirecTV doesn't renew its NFL Sunday Ticket package.
Campbell Soup (CPB) fell after posting weaker-than-expected quarterly sales and lowered earnings guidance for the year.
World Entertainment Wrestling (WWE) move lower after opening higher. The company hosted a conference call late morning to discuss the company's 2014 and 2015 business outlook. It declined to provide updated subscriber guidance, saying it was sticking to quarterly guidance.
Ryanair (Irish Stock Exchange: RY4B-IE) soared after it said strong demand this summer would help lift profits by up to 20 percent this year. This came after the company reported its first decline in profits in five years.
Intermune (ITMN) hit a 52-week high after its experimental drug to treat a fatal lung disorder showed positive results in a late stage trial.
Lifelock (LOCK) plummeted after the fraud and protection services provider temporarily suspended its Lemon Wallet, after it failed to meet the company's security standards.
Walgreen (WAG) gained ground after denying a report of speeding up its Boots takeover.
DeutscheBank (XETRA:DBK-DE) fell on news it asked shareholders for $11 billion in new cash to strengthen its balance sheet.
Credit Suisse (Swiss Exchange: CSGN-CH) moved lower. Reuters reported that the company's guilty plea with the U.S. to pay over $2 billion to resolve charges that it helped Americans avoid paying taxes would be announced after the market close Monday.
Johnson Controls (JCI) rose on news it agreed to sell its auto interiors business to a joint venture its forming with a unit of China's biggest automaker.
Delphi (DLPH) gained ground after being added to the "best ideas" list at Morgan Stanley, which also increased its price target to $85 from $62.
Gogo (GOGO) moved higher after UBS upgraded the stock to "buy" from "neutral," citing valuation.
Abbott Labs (ABT) climbed after the company said it would acquire Chile's CFR Pharmaceuticals for $2.9 billion that will more than double its branded generic business in Latin America.
-By CNBC's Rich Fisherman.